Outlook Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $OTLK in the last 30 days.
See all $OTLK insider activity →Outlook Therapeutics (OTLK) appointed Greg DiPasquale as Chief Commercial Officer to lead U.S. commercialization of LYTENAVA, expected to launch by end of 2026 for wet AMD patients. According to the company, this is a step toward commercialization.
Outlook Therapeutics (OTLK) announced Kevin Lundquist as its new CFO, emphasizing his role in the upcoming U.S. launch of FDA-approved LYTENAVA for wet AMD. The company is transitioning from development to commercialization, though specific launch timing and sales metrics are not yet disclosed.
Outlook Therapeutics (OTLK) submitted an application to CMS for a permanent J-code for LYTENAVA, its treatment for wet age-related macular degeneration. The company aims for a U.S. launch before year-end 2026. A J-code would simplify billing but does not guarantee coverage or reimbursement.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning OTLK (Outlook Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent OTLK coverage spans regulation, financial news and corporate actions.
The executive hire signals progress toward product launch but does not immediately change financials.
The CFO appointment signals leadership stability as the company moves toward commercialization, which may support modest upside.
The filing introduces uncertainty about future Medicare reimbursement, which may weigh on the stock.
If CMS grants a permanent J‑code, reimbursement pathways improve, potentially supporting the stock price ahead of the 2026 launch.
The new pricing may affect margins and demand for the drug.
AlphAI scores every news story that mentions OTLK with an AI model for sentiment and relevance, and aggregates insider trades from Outlook Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Outlook Therapeutics (OTLK) appointed Greg DiPasquale as Chief Commercial Officer to lead U.S. commercialization of LYTENAVA, expected to launch by end of 2026 for wet AMD patients. According to the company, this is a step toward commercialization.
1 min readOutlook Therapeutics (OTLK) announced Kevin Lundquist as its new CFO, emphasizing his role in the upcoming U.S. launch of FDA-approved LYTENAVA for wet AMD. The company is transitioning from development to commercialization, though specific launch timing and sales metrics are not yet disclosed.
1 min readOutlook Therapeutics (OTLK) submitted an application to CMS for a permanent J-code for LYTENAVA, its treatment for wet age-related macular degeneration. The company aims for a U.S. launch before year-end 2026. A J-code would simplify billing but does not guarantee coverage or reimbursement.
2 min readOutlook Therapeutics (OTLK) submitted an application to CMS for a permanent J-code for LYTENAVA, its FDA-approved treatment for wet age-related macular degeneration. The company aims to launch LYTENAVA in the U.S. by year-end 2026, with the J-code submission supporting reimbursement and market access strategies. LYTENAVA is already approved in the EU and UK.
2 min readOutlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
1 min readOutlook Therapeutics (OTLK) presented its commercial strategy for LYTENAVA, its newly FDA-approved eye drug, at the H.C. Wainwright conference. The company aims for a focused launch targeting practices dissatisfied with repackaged bevacizumab, with pricing under $500 per dose. Success hinges on payer access and a permanent billing code expected in 2027. OTLK's stock has fallen 58% year-to-date but rebounded 57% in six months, with a market cap of $161M. The company remains unprofitable, with neg
2 min readOutlook Therapeutics (OTLK) shares surged 140% after the FDA granted its appeal for Lytenava, an eye disease drug. The company plans to resubmit its BLA in 2026. Directors bought shares, and the company raised $5M in a direct offering. OTLK stock is up sharply this week but down 54% over the past year.
2 min readOutlook Therapeutics (OTLK) granted its CFO 500,000 stock options at $0.63 per share, expiring in 2036. The options vest over 4 years, with 25% vesting in 2027. The grant was made as an employment inducement under Nasdaq rules.
1 min readU.S. stock futures rose early Monday due to reports of a U.S.-Iran ceasefire, easing fears and leading to a crude oil price drop. Key companies like Nvidia (NVDA), Oracle (ORCL), and Outlook Therapeutics (OTLK) saw premarket movements. The week ahead includes major tech earnings and Fed decisions.
2 min readOutlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Transition On August 23, 2026, Outlook Therapeutics, Inc. (the “Company”) and Lawrence A. Kenyon, t
1 min read
